Last updated on January 2019

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)


Brief description of study

The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme (galsulfase) treatment; to further characterize the long-term safety of Naglazyme treatment.

Clinical Study Identifier: NCT00214773

Find a site near you

Start Over